Streetbeat News

WGS

GeneDx Holdings Corp.

http://www.genedx.com

Industry

Medical - Healthcare Information Services

GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.

Open

90.93

Mkt cap

2.8B

Volume

915K

High

101.19

P/E Ratio

-50.76

52-wk high

115.60

Low

90.20

Div yield

N/A

52-wk low

7.72

GeneDx (NASDAQ:WGS) has announced significant enhancements to its Whole Genome Sequencing (WGS) product, including faster turnaround times for Rapid Whole Genome Sequencing (rWGS), the addition of buccal sample types, and expanded repeat expansions. These improvements aim to accelerate diagnoses and improve patient outcomes.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 8:45 pm

GeneDx Holdings Corp. (NASDAQ:WGS) has led the Russell 2000 Index in 2024 with a 1,101% increase in share price, driven by a shift to more comprehensive genetic testing. Goldman Sachs has raised its price target for GeneDx from $12.50 to $28, maintaining a Neutral rating. Other top performers include Corbus Holdings Inc. (NASDAQ:CRBP) and Root, Inc. (NASDAQ:ROOT).

Portfolio Pulse from Michael Juliano

July 18, 2024 | 5:36 pm

In the past three months, 6 analysts have released ratings for GeneDx Holdings (NASDAQ:WGS), with a mix of bullish and neutral sentiments. The average 12-month price target has increased significantly to $27.33 from $14.30. Analysts from firms like Goldman Sachs, Craig-Hallum, BTIG, and TD Cowen have raised their price targets, reflecting positive outlooks. Despite strong revenue growth, GeneDx faces challenges with profitability and returns.

Portfolio Pulse from Benzinga Insights

July 17, 2024 | 5:01 pm

Goldman Sachs analyst Matthew Sykes maintains a Neutral rating on GeneDx Holdings (NASDAQ:WGS) and raises the price target from $12.5 to $28.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2024 | 4:05 pm

Analysts have provided mixed ratings for GeneDx Holdings (NASDAQ:WGS) in the latest quarter, with a majority being bullish. The average 12-month price target has increased by 60% to $20.8. Key analysts have raised their price targets, reflecting positive sentiment towards the company's future performance.

Portfolio Pulse from Benzinga Insights

June 26, 2024 | 2:01 pm

BTIG analyst Mark Massaro maintains a Buy rating on GeneDx Holdings (NASDAQ:WGS) and raises the price target from $19 to $35.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 12:25 pm

GeneDx has announced a new collaboration with Epic to expand access to rapid whole genome sequencing (WGS) in Neonatal Intensive Care Units (NICUs). This partnership aims to enhance the integration of GeneDx's services with health systems using Epic's Electronic Health Records (EHR).

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 12:36 pm

Insiders have made significant purchases in PBF Energy, GeneDx Holdings, and Northwest Bancshares, indicating confidence in these companies' prospects. PBF Energy's 10% owner acquired $12.6 million worth of shares, GeneDx Holdings' director bought $2.76 million worth of shares, and Northwest Bancshares' director purchased $128,166 worth of shares.

Portfolio Pulse from Avi Kapoor

June 06, 2024 | 12:59 pm

GeneDx has launched a unique Patient Access Program in collaboration with leading biopharma companies to enhance access to exome sequencing for pediatric epilepsy patients.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 11:51 am

Insiders have made significant purchases in ProFrac Holding Corp., Global Partners LP, and GeneDx Holdings Corp., indicating confidence in these companies' prospects. ProFrac's Dan H. Wilks acquired 460,000 shares, Global Partners' Global GP LLC acquired 30,000 shares, and GeneDx's Casdin Partners bought 170,000 shares.

Portfolio Pulse from Avi Kapoor

May 29, 2024 | 11:56 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.